(EMAILWIRE.COM, January 03, 2018 ) Publisher' latest market research report titled Bio Pharma Market in India 2017 states that while historically the biopharmaceuticals market in the country grew at a CAGR of 15.7%, it is expected to grow at a CAGR of 13.6% between 2016 and 2022. With a large portion of the population falling in the senior citizen category, the need for various healthcare services and pharmaceutical products, including biopharmaceuticals is expected to rise in the country. Moreover, with increased life expectancy, this segment of the population is expected to grow further in the coming years. The increased disposable income of Indians is also allowing them to spend more on medicines and follow medication more diligently. Also, growing health awareness among individuals is resulting in early detection of various medical conditions, and leading to individuals being subject to various medications much earlier than before..

However, the lack of regulatory clarity acts as a major challenge for the industry. The regulation of biopharmaceuticals is inefficient and complex due to the involvement of multiple agencies and committees in the review and approval process. Competition from other Asian countries also acts as a challenge for the Indian bio pharma market. Despite the competition from other countries, India's biotechnology sector has attracted major investments from several global companies due to its strong generic biotechnology potential. While Indian Immunologicals Ltd. set up vaccine manufacturing facilities in Pondicherry and Hyderabad by investing INR 3 bn and INR 2.5 bn respectively, Shantha Biotechnics Pvt. Ltd. built an insulin product manufacturing facility entailing an investment of INR 4.6 bn. The country is being recognized globally as a preferred outsourcing destination for contract research and manufacturing services. This will further aid in the development of the country's bio pharma sector. Biocon Ltd., Dr. Reddy's Laboratories Ltd, Serum Institute of India Pvt. Ltd., Lupin Ltd. and Intas Pharmaceuticals Ltd. are some of the major companies operating in this market.

Get Free Sample of this Report http://www.reportsweb.com/inquiry&RW00011190720/sample

Coverage:
Overview of the bio pharma market in India, and historical and forecasted market size data over 2010 to 2022
Trade analysis of bio pharma products in India
Qualitative analysis of the major drivers and challenges affecting the market
Analysis of the competitive landscape and profiles of major players operating in the market
Key recent developments in the Indian bio pharma sector

Why Buy-
Get a broad understanding of the bio pharma sector in India, the dynamics of the market and the current state of the sector
Strategize marketing, market-entry, market expansion and other business plans by understanding the factors driving the growth of the market
Be informed regarding the key developments in the Indian bio pharma sector
Understand major competitors' business and market dynamics, and respond accordingly

Get complete access of this report@ http://www.reportsweb.com/bio-pharma-market-in-india-2017

Bio Pharma Market Company Profiling
Public Companies
1. Biocon Ltd.
2. Cadila Healthcare Ltd.
3. Dr. Reddy's Laboratories Ltd.
4. GlaxoSmithKline Pharmaceuticals Ltd.
5. Lupin Ltd.
6. Wockhardt Ltd.

Private Companies
1. Haffkine Bio-Pharmaceutical Corporation Ltd.
2. Intas Pharmaceuticals Ltd.
3. Reliance Life Sciences Pvt. Ltd.
4. Serum Institute of India Pvt. Ltd.         

Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results